#62023TJ1183Genel Mahkeme'nin (Dördüncü Daire) 11 Şubat 2026 tarihli Kararı.
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
🇬🇧 English
The General Court ruled to revoke the marketing authorization for Dimethyl Fumarate Polpharma, a medication used for human treatment. This decision affects the pharmaceutical company Polpharma and potentially impacts patients who rely on this medication. The ruling is based on compliance with European medicinal product regulations.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Revocation of marketing authorization for Dimethyl Fumarate Polpharma
- Compliance with Directive 2001/83/EC and Regulation (EC) No 726/2004
- Implications for patients relying on this medication
Affected Parties
PolpharmaPatients using Dimethyl Fumarate
Tags
pharmaceuticals,regulation,court ruling